stockrow
Saturday 7 November 2026
Export GYRE’s income statement to Excel — free account
Gyre Therapeutics, Inc.
GYRE Healthcare Biotechnology
- Revenue
- +7.75%
- EPS
- −200.0%
- Free cash flow
- −129.9%
Quarter to September 2026, against a year earlier
4.72
0.71
+17.71%
Follow GYRE
Alert me
| Sep '26 From the 10-Q filed 6 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
2 | 2 | 5 | 4 |
+8 more TTM periods Free account |
| (18.54%) | (13.58%) | (5.27%) | 6.37% | ||
| (14.49%) | (10.50%) | (4.36%) | 2.91% | ||
ROIC |
— | (8.51%) | (0.10%) | 7.50% | |
Return on Tangible Assets |
(21.45%) | (15.30%) | (6.66%) | 3.28% | |
Average Days of Receivables |
0.00 | 85.65 | 71.70 | 98.02 | |
Free Cash Flow per Share |
(0.23) | (0.07) | 0.03 | (0.01) | |
Free Cash Flow |
(24.28) | (7.12) | 3.07 | (0.88) | |
Capital Expenditures |
(1.12) | (2.19) | (1.25) | (1.89) | |
| Other line items | |||||
Cash ROIC |
0.00% | (2.97%) | 1.64% | (0.31%) | |
Accounts Receivable Turnover |
0.00 | 4.52 | 5.40 | 4.16 | |
Accounts Payable Turnover |
4.46 | 10.42 | 29.71 | 7.51 | |
Inventory Turnover |
0.68 | 0.67 | 0.60 | 0.66 | |
Average Days of Payables |
135.02 | 66.28 | 16.82 | 89.97 | |
Days of Inventory on Hand |
625.87 | 612.78 | 720.73 | 685.45 | |
Tax Rate |
0.11 | 0.28 | (7.58) | (0.32) | |
Research and Development Expense of Revenue |
0.00% | 23.56% | 14.82% | 11.75% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 75.97% | 78.21% | 73.75% | |
Share Based Compensation of Revenue |
9.03% | 8.27% | 7.89% | 6.14% | |
Interest Coverage |
— | (6.52) | — | — | |
Operating CF/Net income |
0.89 | 0.27 | (0.68) | 0.20 | |
Depreciation/Fixed assets |
0.00 | 0.12 | 0.11 | 0.09 | |
Capex/Depreciation |
0.00 | (0.69) | (0.47) | (0.75) | |
Revenue per Share |
1.15 | 1.19 | 1.28 | 1.30 | |
Operating CF per Share |
(0.22) | (0.05) | 0.05 | 0.01 | |
Capex per Share |
(0.01) | (0.02) | (0.01) | (0.02) | |
Capex to Sales |
0.01 | 0.02 | 0.01 | 0.02 |
Columns are period end dates · fundamentals updated 6 Nov 2026